Castle Biosciences
CSTL
160 hedge funds and large institutions have $988M invested in Castle Biosciences in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 72 increasing their positions, 42 reducing their positions, and 20 closing their positions.
5,900% more call options, than puts
Call options by funds: $480K | Put options by funds: $8K
71% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 42
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
8% more capital invested
Capital invested by funds: $916M → $988M (+$72.2M)
4.96% more ownership
Funds ownership: 84.8% → 89.76% (+5%)
1% more funds holding
Funds holding: 159 → 160 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$25.1M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$13.5M |
| 3 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$9.54M |
| 4 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
+$8.78M |
| 5 |
GPGA
Grandeur Peak Global Advisors
Salt Lake City,
Utah
|
+$8.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$10.1M |
| 2 |
Two Sigma Investments
New York
|
-$5.8M |
| 3 |
Renaissance Technologies
New York
|
-$4.52M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
-$4.36M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$4.36M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
| – | -$5K | -108 | Closed |
|
|
DFCM
177
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | -$4K | -87 | Closed |
|
|
TCM
178
Tradewinds Capital Management
Bellingham,
Washington
| – | +$207 | +5 | New |
|
|
CAL
179
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$331 | +8 | New |
|
CSTL Hedge Fund Activity: Q1 2022 in Review
160 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q1 2022, worth a combined $988M — up 7.9% from $916M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CSTL positions and 20 closed out — a net gain of 3 holders — while 72 added to existing stakes and 42 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $25.1M. The largest seller was Millennium Management, cutting an estimated $10.1M.
- 160 institutional investors held Castle Biosciences (CSTL) as of Q1 2022, up from 159 in Q4 2021.
- Funds reported $988M of Castle Biosciences stock for Q1 2022, up 7.9% quarter-over-quarter.
- 23 funds opened new Castle Biosciences positions in Q1 2022 and 20 closed out, a net change of +3 holders.
- The largest Castle Biosciences buyer in Q1 2022 was Bellevue Group, an estimated $25.1M added.
- The largest Castle Biosciences seller in Q1 2022 was Millennium Management, an estimated $10.1M sold.
Based on aggregated 13F filings for Q1 2022.